Repligen Corporation (NASDAQ:RGEN - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Repligen in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda forecasts that the biotechnology company will post earnings of $0.47 per share for the quarter. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's Q2 2026 earnings at $0.52 EPS, Q3 2026 earnings at $0.52 EPS and Q4 2026 earnings at $0.66 EPS.
A number of other research analysts have also recently commented on RGEN. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target on the stock. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Royal Bank Of Canada dropped their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.75.
View Our Latest Stock Report on RGEN
Repligen Price Performance
Shares of RGEN stock traded down $2.55 during trading on Friday, hitting $121.49. The company had a trading volume of 71,670 shares, compared to its average volume of 724,447. The firm has a market capitalization of $6.83 billion, a P/E ratio of -269.00, a price-to-earnings-growth ratio of 3.43 and a beta of 1.11. Repligen has a one year low of $102.97 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The stock's 50-day moving average price is $124.79 and its 200 day moving average price is $138.70.
Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 earnings per share.
Hedge Funds Weigh In On Repligen
A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after acquiring an additional 594,189 shares during the period. Groupama Asset Managment raised its position in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after acquiring an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Repligen in the 4th quarter valued at about $53,428,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Repligen during the 4th quarter valued at about $52,492,000. 97.64% of the stock is currently owned by institutional investors.
Repligen Company Profile
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
